The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...
AstraZeneca AZN announced that the FDA has approved its antibody-drug conjugate (ADC), datopotamab deruxtecan (or Dato-DXd), ...
The approval was based on results from the TROPION-Breast01 Phase III trial.
Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) has been approved by the US Food and Drug ...
(Alliance News) - AstraZeneca PLC on Monday said Datroway has been approved in the US for patients with a type of breast cancer. The Cambridge-based pharmaceuticals firm explained the final approval ...
British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...
Daiichi Sankyo shares rose sharply after the U.S. Food and Drug Administration approved its breast cancer drug Datroway. Shares were recently 8.7% higher at 4,437 yen, equivalent to $28.39, on Monday ...
The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a ...
The Food and Drug Administration approved the drug for patients with advanced breast tumors whose cells bear a certain ...
Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...